Drug Database · Clinicians

Nimesulide

Brands (2) Nidolid, SulidinShow all

Anti-inflammatory and antirheumatic agent (non-steroid); Non-steroidal anti-inflammatory drug (NSAID) PH FDA category

Contraindicated if CrCl <30Rx · Prescription drug2 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Contraindications

  • CrCl below 30 mL/min
  • Hepatic impairment; history of nimesulide hepatotoxicity
  • Active or recurrent ulcer, gastrointestinal or other active bleeding, bleeding disorders
  • Severe heart failure
  • Aspirin or NSAID hypersensitivity
  • Children under 12 years
  • Third trimester of pregnancy; breastfeeding
renalcarematters.com, reviewed

Dosing: Adult

  • Acute pain; primary dysmenorrhea (adults and adolescents 12 years and older). Second-line only: use only when other NSAIDs or analgesics are not suitable. No longer approved in Europe for osteoarthritis (EMA 2012).: 100 mg twice daily after meals for the shortest time possible; maximum 15 days per course (EMA 2007/2012)
renalcarematters.com, reviewed

Dosing: Altered kidney function

Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) restricted in Europe since 2007 and 2012 (second-line, acute pain or primary dysmenorrhea only, maximum 15 days) because of liver injury. About half a dose is excreted in urine; in mild to moderate kidney impairment exposure rises about 50% without accumulation. The European harmonized text needs no change at creatinine clearance (CrCl) 30–80 mL/min and contraindicates it below 30 mL/min. It has no US FDA label.

Kidney function measure: European harmonized summary of product characteristics (EMA 2004; kidney thresholds unchanged by the 2007 and 2012 reviews) uses creatinine clearance (CrCl, mL/min). Indications and duration follow EMA 2012.

Show full dosing details
CrCl ≥60 mL/min
Usual: 100 mg twice daily after meals, maximum 15 days; second-line for acute pain or primary dysmenorrhea only (EMA 2012).
CrCl 30–59 mL/min
CrCl 30–80: no dose adjustment (EMA 2004). Caution: kidney function may deteriorate; stop if it does.
CrCl 15–29 mL/min
Contraindicated: CrCl <30 mL/min (EMA 2004 Annex III, 4.2/4.3).
CrCl <15 mL/min (not on dialysis)
Contraindicated: CrCl <30 mL/min (EMA 2004 Annex III, 4.2/4.3).
Hemodialysis (intermittent)
Contraindicated (severe kidney impairment).
Peritoneal dialysis
Contraindicated (severe kidney impairment).
CRRT
Contraindicated; NSAIDs worsen acute kidney injury.
  • Dialyzable? Not stated (up to 97.5% protein-bound).
  • Monitoring Liver injury risk: maximum 15 days, second-line only. Liver function: stop permanently at any sign of liver injury or abnormal liver tests; avoid other hepatotoxic drugs and alcohol. Kidney function in CKD and heart failure; gastrointestinal bleeding (EMA 2004, 4.4).
Children (kidney dosing)
eGFR ≥60
Contraindicated under 12 years; adolescents follow adult kidney rules (contraindicated if CrCl <30).
eGFR 30–59
Contraindicated under 12 years; adolescents follow adult kidney rules (contraindicated if CrCl <30).
eGFR 15–29
Contraindicated under 12 years; adolescents follow adult kidney rules (contraindicated if CrCl <30).
eGFR <15 (not on dialysis)
Contraindicated under 12 years; adolescents follow adult kidney rules (contraindicated if CrCl <30).
Hemodialysis (intermittent)
Contraindicated under 12 years; adolescents follow adult kidney rules (contraindicated if CrCl <30).
Peritoneal dialysis
Contraindicated under 12 years; adolescents follow adult kidney rules (contraindicated if CrCl <30).
CRRT
Contraindicated under 12 years; adolescents follow adult kidney rules (contraindicated if CrCl <30).

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: EMA product information (2004). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Contraindicated under 12 years; adolescents 12 to 18 years as adults (EMA 2004).
Usual dose
12 to 18 years: 100 mg twice daily.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Topical gel: 10 mg/g
  • Transdermal gel: 20 mg/g

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Nimesulide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Nimesulide
Package insert
NidolidNimesulide
20mg/g (2% w/w) Transdermal GelAluminum Tube x 30g (Box of 1's); Aluminum Tube x 60g (Box of 1's); Aluminum Tube x 10g (Physician's sample) (Box of 1's)
Rx
Polipharm Co., Ltd.Thailand
PACIFIC HEALTHCARE PHILIPPINES, INC.
DR-XY35798
May 11, 2029
SulidinNimesulide
10 mg/g (1% w/w) Topical Gel15 g Laminated Polyfoil Tube (Box of 1's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Embil International Philippines, Inc.
DRP-8029
Nov 16, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Warfarin, other anticoagulants, aspirinAvoidMore bleeding.Not recommended.
Other NSAIDs, analgesics; hepatotoxic drugs; alcoholAvoidMore gastrointestinal or liver toxicity.Avoid combining.
MethotrexateAvoidMethotrexate toxicity.Avoid within 24 hours of nimesulide.
FurosemideAdjust or monitorDiuretic effect reduced.Use with caution.
LithiumAdjust or monitorHigher lithium levels.Monitor lithium closely.
CyclosporineAdjust or monitorMore nephrotoxicity.Monitor kidney function.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Serious

  • Serious liver injury, including very rare fatal cases
  • Gastrointestinal bleeding, ulceration, perforation
  • Kidney function deterioration
renalcarematters.com, reviewed

Monitoring parameters

  • Liver injury risk: maximum 15 days, second-line only. Liver function: stop permanently at any sign of liver injury or abnormal liver tests; avoid other hepatotoxic drugs and alcohol. Kidney function in CKD and heart failure; gastrointestinal bleeding (EMA 2004, 4.4). Kidney
  • Liver injury risk: maximum 15 days per course, second-line only
  • Hepatotoxicity risk rises with duration over 15 days and higher doses; do not rechallenge after liver injury
  • Liver tests if any symptoms; stop permanently if abnormal
  • Kidney function
  • Gastrointestinal bleeding
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Time to peak2 to 3 hours
Half-lifeAbout 3.2 to 6 hours
Half-life in kidney failure (ESKD) kidneyAUC and half-life about 50% higher in mild to moderate impairment, no accumulation
Protein bindingUp to 97.5%
Metabolism (CYP, transporters)Hepatic including CYP2C9
Active metabolitesMain metabolite (hydroxy) is active
Renal excretion kidneyAbout 50% in urine, 29% in feces
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. European Medicines Agency. Nimesulide Article 31 referral Annex III (CPMP/3086/03-REV.1) [EMA product information, 2004; no US FDA label]. https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-annex-iii_en.pdf-0
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. European Medicines Agency. (2004). Nimesulide: Article 31 referral, Annex III (summary of product characteristics; CPMP/3086/03-REV.1). https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-annex-iii_en.pdf-0
  4. European Medicines Agency. (2012). Questions and answers on the review of systemic medicines containing nimesulide (EMA/CHMP/382884/2011 Rev. 1; Commission decision January 20, 2012). https://www.ema.europa.eu/en/documents/referral/questions-answers-review-systemic-medicines-containing-nimesulide_en.pdf
  5. European Medicines Agency. (2012). Nimesulide (systemic): Article 31 referral [Referral page; CHMP opinion June 23, 2011; Commission decision January 20, 2012]. Retrieved November 17, 2026. https://www.ema.europa.eu/nl/medicines/human/referrals/nimesulide-1
  6. Donati, M., Conforti, A., Lenti, M. C., Capuano, A., Bortolami, O., Motola, D., Moretti, U., Vannacci, A., Rafaniello, C., Vaccheri, A., Arzenton, E., Bonaiuti, R., Sportiello, L., & Leone, R. (2016). Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: Data from drug-induced liver injury case-control study in Italy. British Journal of Clinical Pharmacology, 82(1), 238–248. https://doi.org/10.1111/bcp.12938

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .